Lung cancer (LC) is the most common cause of cancer death in the world. A great challenge in treating NSCLC is the discovery of advanced, molecular tools to diagnose the disease in early stages as well as the development of immunotherapy. MicroRNAs are regulatory molecules (~20 nt in length) with the ability to regulate the expression of genes. The recently described PD-1 and PD-L1 molecules have great importance for potential use in immunotherapy of many cancers. These molecules are associated with immune checkpoints and provide an opportunity for the treatment of advanced NSCLC patients with synthetic monoclonal antibodies. PD-L1 expression is strictly associated with microRNA function in lung cancer cells. The group of microRNAs related to PD-L1 includes, among others, miR-200, miR-197 or miRNA-34. Expression of these molecules may be useful in lung cancer diagnosis, qualification to anti-PD-1 or anti-PD-L1 antibody therapy and could be a potential therapeutic target. However, studies on PD-L1-related microRNAs are necessary to develop advanced targeted molecular therapies.
Introduction
Lung cancer (LC) is the most common cause of cancer death in the world and is frequently diagnosed in advanced stages with poor prognosis. Some of the molecular changes predisposing to molecularly targeted therapy could prolong overall survival of patients with advanced non-small cell lung cancer (NSCLC). The challenge for NSCLC treatment is the discovery of advanced, molecular tools to diagnose the disease in early stages as well as the development of immunotherapy. MicroRNAs -widely described regulatory molecules complementary to mRNA of tumour suppressor genes or oncogenes -provide this possibility. They are~20 nt in length, but their expression may characterize cancers in different stages, even precancerous lesions. The recently described PD-1 and PD-L1 molecules are of great importance for potential use in immunotherapy of melanoma, NSCLC, renal and urothelial cancers, as well as head and neck cancer. The immunological synapse formation between lymphocytes (PD-1) and tumour-or antigen-presenting cells (PD-L1, PD-L2, B7-1) causes cytotoxic T cell anergy in tumour microenvironment and lymph nodes and allows for further tumour progression. Blockage of these immunological checkpoints by synthetic monoclonal antibodies (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab) gives new treatment opportunities for patients with advanced NSCLC. However, some miRNAs are also strictly specific to PD-1 and PD-L1 mRNA and have diagnostic potential and therapeutic use.
There are several advanced possibilities of NSCLC diagnosis and treatment; however, small cell lung cancer (SCLC) seems to be forgotten. SCLC affects 15% of lung cancer patients and is characterized by rapid progression and poor prognosis [1] . It is usually diagnosed in advanced stages with metastasis. Standard treatment of SCLC based on chemotherapy is insufficient. Consequently, new therapeutic strategies are urgently required, including molecular personalized drugs and immunotherapeutics [2] .
In this review, we describe new opportunities of lung cancer diagnosis and therapy using the latest discoveries in biology and medicine, that is microRNA molecules and their role in the induction of anti-tumour immune responses. The possibility of using microRNAs as predictive factors for immune checkpoint inhibitors appears to be a distant future. Further discoveries may reveal the possibility of administering microRNAs as immunotherapeutic agents due to their ability of silencing the expression of various genes, including those encoding immune checkpoints.
Biogenesis and activity of microRNA
Genes encoding microRNAs are located in the whole genome, including introns, exons or intergenic sequences [3, 4] . They can be transcribed separately or as polycistronic transcriptional units. Two steps of microRNA biogenesis are distinguished. The first one, consisting of transcription and primary pre-microRNA transcript formation, is conducted in the nucleus. The following second step is a cytoplasmic process leading to the formation of mature microRNA -an enzymatically active complex containing AGO2 proteins with slicer activity [5] . MicroRNAs silence gene expression by targeting 3 0 -UTR (3 0 -untranslated region) of their mRNA [6, 7] . When connection between microRNA and 3-UTR is imperfect, it leads to cleavage of transcripts or inhibition of translation. Epigenetics is defined as mitotically and meiotically heritable changes in gene expression that do not involve a change in the DNA sequence. microRNA has been shown to regulate epigenetic mechanisms. As microRNAs regulate almost every cellular process in the body, they play an important part in maintaining tissue homoeostasis. These molecules regulate almost all processes in human body. Disruption of microRNA expression can lead to different diseases including different types of cancer. At present, more than two and a half thousand mature microRNA sequences are known (according to the Sanger Database Release 21). MicroRNA activity networks are complex, as one micro-RNA can regulate the expression of approximately two hundred genes [8, 9] . Moreover, one transcript can be regulated by several complementary microRNAs. This property results in the ability of one microRNA to simultaneously act as a tumour suppressor as well as an oncogene [10, 11] .
Numerous studies have reported microRNAs as a potentially powerful diagnostic, prognostic and predictive factor in patients with cancer [12, 13] . MicroRNA molecules are present in body fluids: cerebrospinal fluid, urine, human milk, saliva and most importantly in plasma (circulating microRNA). It is known that disrupted microRNA expression in tumour cells could be reflected in microRNA profile in plasma. This makes microRNAs a potential non-invasive cancer biomarker. Several studies have demonstrated that the disruption of microRNA expression may serve as a potential powerful marker for diagnosing different histological types of lung cancer, even in early stages, for example microRNA-21 and microRNA-200 family [14] [15] [16] .
PD-L1 activity in lung cancer -immunological events
The PD-L1 (Programmed cell death ligand 1) gene encodes the transmembrane protein PD-L1. PD-L1 is highly expressed on antigen-presenting cells under physiological conditions. The presence of this protein prevents the autoimmune reaction (provides self-tolerance). PD-1, located on lymphocytes, blocks the lymphocyte action pathway by binding to PD-L1. It inhibits cytokine and proteolytic enzyme secretion by cytotoxic T cells and prevents the destruction of own cells expressing PD-L1.
It has been proven that cancer cells have the capacity to express PD-L1 [17] . This allows them to 'hide' from the action of the immune system. Interestingly, certain cytotoxic agents (docetaxel, paclitaxel, etoposide) contribute to the increased expression of PD-L1 on tumour cells [18] . Therefore, application of monoclonal anti-PD-1 or anti-PD-L1 antibodies might be a good solution for patients with NSCLC, previously treated with chemotherapy. Other studies have shown that platinum-based chemotherapy decreases the expression of PD-L1 on tumour cells. Moreover, pembrolizumab is an effective compound also in naive patients, whose tumour cells express PD-L1 [19] .
It is very probable that in the future it will be possible to use more sophisticated molecular therapies involving non-coding microRNAs targeting PD-L1 mRNA.
MicroRNA-200 family and regulation of PD-L1 expression
MicroRNA-200 is a family of five molecules: miR-200a, miR-200b, miR-429 (locus 1p36.33), miR-200c and miR-141 (locus 12p13.31). They participate in epithelialmesenchymal transition (EMT), which is essential for tumour metastasis. They negatively regulate the expression of EMT-inducing transcription factors zinc finger E-box binding homeobox 1 and 2 genes (ZEB1 and ZEB2) leading to a high expression of E-cadherin involved in cell-cell adhesion via adherent junction formation [20] . In normal cells, betacatenin tethers E-cadherin to cytoskeleton. E-cadherin and beta-catenin form a complex that prevents cell migration. These processes are blocked in cancer [21, 22] . A negative feed-back loop mechanism is part of this regulation: miR-200 regulates ZEB1/ZEB2 expression and ZEB1/ZEB2 acts simultaneously as microRNA-200 repressor (Fig. 1) [23]. Chen et al. [24] confirmed that abnormalities in miR-200/ZEB1 regulatory axis are closely related to tumour cell exit to the bloodstream and metastasis. ZEB1/ZEB2 is involved in the regulation of circulating tumour cells (CTC) to survive under severe bloodstream conditions. CTC in the blood cannot adhere to stromal cells, thus they must function in solitude. Therefore, they reprogram their gene expression to survive in the bloodstream and avoid apoptosis and anoixis. It is a prerequisite to these cells to move to distant tissues and trigger secondary tumour formation.
Currently, the main attention of diagnosticians and clinicians is paid to the regulation of PD-L1 expression in tumour cells [24] [25] [26] . Expression of this immunological molecule is strictly related to microRNA function in lung cancer cells. Gibbons et al. and Chen et al. [24, 26] reported that the microRNA-200 family was a regulator of PD-L1 expression in NSCLC. Chen et al. [24] found that high PD-L1 expression in primary tumour cells was strongly associated with high mesenchymal score (high EMT score) and could be determined by miR-200 expression. Moreover, these authors indicated that PD-L1 tumour expression in NSCLC was regulated by the miR-200/ZEB1 axis [24] . It was demonstrated that miR-200 acted as a cell-autonomous suppressor of EMT and metastasis, and directly targeted PD-L1. Moreover, Chen et al. [24] also showed that PD-L1 expression in mesenchymal lung cancer cells was generally higher compared to expression in lung carcinoma cells. Furthermore, they found that stable, inducible or transient miR-200 expression (or ZEB1 silencing) suppressed PD-L1 expression in mesenchymal lung cancer cells. In addition, PD-L1 expression was upregulated in non-metastatic epithelial cells during constitutive ZEB1 expression [24] . In those cases, the authors found that tumour growth and metastasis were inhibited, while the number of intratumoural CD8+ T cells was elevated [24] . Gibbons et al. focused on the ability of tumour cells to create immunosuppressive microenvironment. These authors confirmed that low expression of miR-200 was associated with increased PD-L1 expression, and a consequent suppression of CD8+ cell infiltration. This caused strong proliferation and metastasis of tumour cells [26] . These results may suggest that in the future, the assessment of miR-200 expression may be useful for the diagnosis of lung cancer and even in the qualification to therapy with anti-PD-1 or anti-PD-L1 antibodies. Moreover, miR-200 may be a potential therapeutic target.
Other microRNAs and PD-L1 expression regulation
In a recent study, Cortez et al. found that the miRNA-34 family was associated with PD-L1 expression regulation [25] . The latter authors showed that mutated TP53 NSCLC cell lines had significantly higher expression of PD-L1 and lower expression of miR-34a in comparison with cancer cells with wild-type TP53 [25] . Furthermore, these differences concerned only miR-34a expression, whereas no differences were recorded in the expression of microRNA-34* and miR-34b or miR-34c in cells with different TP53 gene status. Cortez et al. [25] also showed that miR-34a bound to 3 0 UTR of PD-L1 mRNA. MRX34, a synthetic miRNA-34, has been recently discovered and examined in the first phase of clinical trial in solid tumours. MRX34 application in the NSCLC mouse model with PD-L1 expression resulted in a decrease of tumoural PD-L1 expression at both mRNA and protein levels. Simultaneously, the administration of MRX34 and radiotherapy elevated CD8+ cell count and reduced tumour infiltration by radiation-induced macrophages and Treg cells. Cortez et al. [25] suggested that the application of miRNA treatment with standard therapy may represent a novel approach in cancer treatment.
Another microRNA involved in PD-L1 regulation is miR-197. Fujita et al. [27] showed that miR-197 expression was significantly lower in lung cancer cell lines than in normal bronchial cell lines (BEAS-2b). Decreased miR-197 level was detected in the PC14 platinum-resistant cell line in comparison with the parental PC12 lung cancer cell line. This may suggest that miR-197 is involved in chemoresistance, tumourigenesis and metastasis. Furthermore, it was found that miR-197 knockdown led to cisplatin and paclitaxel resistance in four independent lung cancer cell lines, but miRNA-197 overexpression induced cell sensitivity to these compounds. Fujita et al. suggested that the occurrence of chemo-resistance in NSCLC patients with high PD-L1 expression may be controlled by miR-197. These authors showed a negative correlation between miRNA-197 and PD-L1 expression, and lower miRNA-197 expression was associated with shorter overall survival of patients with NSCLC. Interestingly, the PD-L1 mRNA has no complementary sequence to the miRNA-197 seed region. However, this microRNA regulates CKS1B (CDC28 Protein Kinase Regulatory Subunit 1B), which is an inducer of cell cycle and cell division [27] . The latter authors hypothesized that CKS1B regulated PD-L1 expression through the cytokine-activated transcription factor, STAT3 (Signal Transducer And Activator Of Transcription 3). STAT3 has the ability to regulate PD-L1 expression by binding to the promoter region of the PD-L1 gene. This molecular dependence indicates that miR-197 activity is associated with oncogenic activation of STAT3 (Fig. 2) [27].
Conclusions
Currently, there are great advances in lung cancer diagnosis using molecular and immunological methods. These include new molecular targets or immune therapies that prolong life and improve its quality. Among modern drugs, there are tyrosine kinase inhibitors or monoclonal antibodies against immune checkpoints. It is very probable that synthetic oligonucleotides, replacing or deactivating microRNAs in lung cancer treatment, will be used in near future. MicroRNAs could function as oncogenes (oncomirs) and their expression in tumour cells is high. Other microRNAs have a tumour suppressor function and their expression in tumour cells is low or abrogated. Having knowledge about miRNA expression in lung cancer (and other cancers) and in normal tissues, one can design drugs that will complement deficiencies in tumour suppression or inactivate oncomirs (anti-miRNA nucleotides, antisense oligonucleotide). Thereby, restoration of the proper functioning of biochemical pathways would contribute to the elimination of tumour cells. The process of miR-drug design is similar to 'traditional' drug discovery and its introduction in clinical practice. Christopher et al. [28] characterized the steps in the development of miR-drugs. Primarily, miRNA signature should be identified in a specific disease, followed by the validation process of loss/ gain of function studies in vitro and in animal models. A further step is in vivo microRNA delivery studies, including pharmacokinetics/pharmacodynamics assessment, according to the ADME scheme (absorption, distribution, metabolism and excretion). The last step is the evaluation of efficacy and safety in clinical trials [28] . Christopher et al. [28] presented the status of microRNA therapeutic development and suggested that miR-10b, miR-221, miR-155 and miR-34 sequences could be used as potential anticancer agents. The first three agents act as anti-miRNA nucleotides. The sequence of miR-34 has immunosuppressive abilities. It should be emphasized that the process of introducing miR-drugs to clinical practice requires interdisciplinary team commitment (molecular biologists, pathologists and clinicians).
